Search Results - "Upadhye Bannore, Trupti"

Intricacies in the Preparation of Patient Doses of [177Lu]Lu-Rituximab and [177Lu]Lu-Trastuzumab Using Low Specific Activity [177Lu]LuCl3: Methodological Aspects by Chakraborty, Avik, Mitra, Arpit, Sahu, Sudeep, Tawate, Megha, Lad, Sangita, Kamaldeep, Rakshit, Sutapa, Upadhye Bannore, Trupti, Gaikwad, Sujay, Dhotre, Geetanjali, Ray, Mukti Kanta, Damle, Archana, Basu, Sandip, Banerjee, Sharmila

“…The development of humanized monoclonal antibodies (MAbs) with Lutetium-177 ([ 177 Lu]Lu 3+ ) has brought a paradigm shift in the arena of targeted therapy of…”
Get full text

Synthesis and evaluation of [177Lu]Lu‐labeled porphyrin loaded PAMAM dendrimer: Impact on tumor uptake and pharmacokinetics by Kumar, Naveen, Guleria, Mohini, Chakraborty, Avik, Amirdhanayagam, Jeyachitra, Bannore, Trupti Upadhye, Damle, Archana, Sarma, Haladhar D., Das, Tapas

“…The objective of the present work is to evaluate the ability of the radiolabeled PAMAM dendrimers (polyamidoamine) towards facilitating the delivery of an…”
Get full text

A robust lyophilized kit for convenient one-step formulation of [68Ga]Ga-DOTA-E−[c(RGDfK)]2 in hospital radiopharmacy for clinical PET imaging by Das, Soumen, Sahu, Sudeep, Chakraborty, Avik, Kamaleshwaran, K.K., Bannore, Trupti Upadhye, Damle, Archana, Chakravarty, Rubel, Chakraborty, Sudipta

“…The present article describes the development of robust lyophilized kit for convenient formulation of [68Ga]Ga-DOTA-E−[c(RGDfK)]2 (E = glutamic acid, R =…”
Get full text

Initial clinical evaluation of indigenous90Y-DOTATATE in sequential duo-PRRT approach (177Lu-DOTATATE and90Y-DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability,90Y-DOTATATE post- PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effects by Parghane, Rahul, Mitra, Arpit, Bannore, Trupti, Rakshit, Sutapa, Banerjee, Sharmila, Basu, Sandip

“…177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) alone has lesser potential in the clinical setting of neuroendocrine tumor (NET) with large bulky…”
Get full text

Initial clinical evaluation of indigenous 90 Y-DOTATATE in sequential duo-PRRT approach ( 177 Lu-DOTATATE and 90 Y-DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability, 90 Y-DOTATATE post- PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effects by Parghane, Rahul V, Mitra, Arpit, Bannore, Trupti Upadhye, Rakshit, Sutapa, Banerjee, Sharmila, Basu, Sandip

“…Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) alone has lesser potential in the clinical setting of neuroendocrine tumor (NET) with large bulky…”
Get full text

Intricacies in the Preparation of Patient Doses of [ 177 Lu]Lu-Rituximab and [ 177 Lu]Lu-Trastuzumab Using Low Specific Activity [ 177 Lu]LuCl 3 : Methodological Aspects by Chakraborty, Avik, Mitra, Arpit, Sahu, Sudeep, Tawate, Megha, Lad, Sangita, Kamaldeep, Rakshit, Sutapa, Upadhye Bannore, Trupti, Gaikwad, Sujay, Dhotre, Geetanjali, Ray, Mukti Kanta, Damle, Archana, Basu, Sandip, Banerjee, Sharmila

“…The development of humanized monoclonal antibodies (MAbs) with Lutetium-177 ([ Lu]Lu ) has brought a paradigm shift in the arena of targeted therapy of various…”
Get full text

Initial clinical evaluation of indigenous 90Y-DOTATATE in sequential duo-PRRT approach (177Lu-DOTATATE and 90Y-DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability,90Y-DOTATATE post- PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effects by Parghane, Rahul, Mitra, Arpit, Bannore, Trupti, Rakshit, Sutapa, Banerjee, Sharmila, Basu, Sandip

“…Abstract 177 Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) alone has lesser potential in the clinical setting of neuroendocrine tumor (NET) with…”
Get full text